Phosphodiesterase 4 inhibitor combined with secukinumab relieves clinical symptoms in patients with psoriasis via regulating p38MAPK activation and the immune response inflammation
{{output}}
Background: The purpose of the present study was to explore the effect of phosphodiesterase 4 (PDE-4) inhibitor combined with secukinumab monoclonal antibody on the activation level of p38 mitogen-activated protein kinases (p38MA... ...
